BIA-ALCL: Breast Implant-Associated with Anaplastic Large Cell Lymphoma
Understanding BIA-ALCL and Your Legal Options
What is BIA-ALCL?
Breast Implant-Associated with Anaplastic Large Cell Lymphoma (BIA-ALCL) is a rare cancer associated with both saline and silicone breast implants.
BIA-ALCL is a type of blood cancer involving the white blood cells, known as lymphocytes. It is a rare, deadly, and aggressive form of non-Hodgkin lymphoma; not a form of breast cancer.
Lymphoma happens if immune system cells, known as lymphocytes grow and multiply out of control throughout the body.
Symptoms often occur years after the implant surgery.
- Swelling around the implant
- Persistent pain
- Fluid buildup
- Asymmetrical breasts
If you have been diagnosed with BIA-ALCL, contact us today to learn more about your rights and legal options.
Who is most at risk?
Medical authorities emphasize that BIA-ALCL is an extremely rare type of cancer. According to a report by the American Society of Plastic Surgeons and the Plastic Surgery Foundation, more than 10 million women worldwide have received breast implants and it is estimated that fewer than 10 cases of BIA-ALCL are diagnosed each year. One study estimates the incidence at 1 in 3 million.
The risk of developing ALCL remains very low for all women, though it is higher for women who have had breast implants.
BIA-ALCL appears to develop more frequently in women with textured implants than in women with smooth-surfaced implants.
As of February 1, 2017, the FDA has received a total of 359 medical device reports (MDRs) of BIA-ALCL, including nine deaths. The FDA’s medical device report indicate that the average time it took to develop ALCL was about 7 years. The FDA urges all incidents of ALCL be reported to their MedWatch program so that they can assist clinicians who are trying to find the cause of breast implant-associated ALCL and the best way to treat it.
In 2011, the FDA identified a possible association between breast implants and the development of anaplastic large cell lymphoma (ALCL), a rare type of non-Hodgkin’s lymphoma. Since 2011, the FDA has strengthened their understanding of this condition and concur with the World Health Organization designation of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) as a rare T-cell lymphoma that can develop following breast implants. At this time, most data suggest that BIA-ALCL occurs more frequently following implantation of breast implants with textured surfaces rather than those with smooth surfaces.+